Alexandra Castilho
Overview
Explore the profile of Alexandra Castilho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sobral P, Carvalho T, Izadi S, Castilho A, Silva Z, Videira P, et al.
RSC Adv
. 2025 Jan;
15(4):2298-2316.
PMID: 39867321
Despite significant strides in improving cancer survival rates, the global cancer burden remains substantial, with an anticipated rise in new cases. Immune checkpoints, key regulators of immune responses, play a...
2.
Schoberer J, Izadi S, Kierein C, Vavra U, Konig-Beihammer J, Ruocco V, et al.
Front Plant Sci
. 2023 Dec;
14:1320051.
PMID: 38089803
Introduction: The Golgi apparatus of plants is the central cellular organelle for glycan processing and polysaccharide biosynthesis. These essential processes are catalyzed by a large number of Golgi-resident glycosyltransferases and...
3.
Izadi S, Gumpelmair S, Coelho P, Duarte H, Gomes J, Leitner J, et al.
Plant Biotechnol J
. 2023 Dec;
22(5):1224-1237.
PMID: 38050338
Immune checkpoint blocking therapy targeting the PD-1/PD-L1 inhibitory signalling pathway has produced encouraging results in the treatment of a variety of cancers. Durvalumab (Imfinzi) targeting PD-L1 is currently used for...
4.
Aigner-Radakovics K, de Sousa Linhares A, Salzer B, Lehner M, Izadi S, Castilho A, et al.
Sci Signal
. 2023 Oct;
16(805):eadg2610.
PMID: 37788323
Lymphocyte activation gene 3 (LAG3) is an inhibitory immune checkpoint receptor that restrains autoimmune and antitumor responses, but its evolutionarily conserved cytoplasmic tail lacks classical inhibitory motifs. Major histocompatibility complex...
5.
Battin C, de Sousa Linhares A, Leitner J, Grossmann A, Lupinek D, Izadi S, et al.
Cancer Immunol Immunother
. 2023 Jun;
72(9):3029-3043.
PMID: 37310433
Targeting co-stimulatory receptors promotes the activation and effector functions of anti-tumor lymphocytes. 4-1BB (CD137/TNFSF9), a member of the tumor necrosis factor receptor superfamily (TNFR-SF), is a potent co-stimulatory receptor that...
6.
Izadi S, Vavra U, Melnik S, Grunwald-Gruber C, Foderl-Hobenreich E, Sack M, et al.
Front Bioeng Biotechnol
. 2023 May;
11:1180044.
PMID: 37207124
SARS-CoV-2 infects human cells via binding of the viral spike glycoprotein to its main cellular receptor, angiotensin-converting enzyme 2 (ACE2). The spike protein-ACE2 receptor interaction is therefore a major target...
7.
Izadi S, Kunnummel V, Steinkellner H, Werner S, Castilho A
J Biotechnol
. 2023 Feb;
365:48-53.
PMID: 36805356
There is a demand for increasing the current manufacturing capacities for recombinant protein-based drugs. Novel expression systems such as plants are being explored as faster, more flexible, and possibly cheaper...
8.
Eidenberger L, Eminger F, Castilho A, Steinkellner H
Front Bioeng Biotechnol
. 2023 Jan;
10:1073455.
PMID: 36619384
While plant-based transient expression systems have demonstrated their potency to rapidly express economically feasible quantities of complex human proteins, less is known about their compatibility with posttranslational modification control. Here...
9.
Izadi S, Javaran M, Rashidi Monfared S, Castilho A
PLoS One
. 2021 Nov;
16(11):e0260796.
PMID: 34847186
Thrombolytic and fibrinolytic therapies are effective treatments to dissolve blood clots in stroke therapy. Thrombolytic drugs activate plasminogen to its cleaved form plasmin, a proteolytic enzyme that breaks the crosslinks...
10.
Gattinger P, Izadi S, Grunwald-Gruber C, Kallolimath S, Castilho A
Front Plant Sci
. 2021 Jul;
12:671728.
PMID: 34305971
The potential therapeutic value of many proteins is ultimately limited by their rapid clearance. One strategy to limit clearance by metabolism and excretion, and improving the stability of therapeutic proteins,...